Pharmaceutical

OCT-461201 by Oxford Cannabinoid Technologies for Visceral Pain: Likelihood of Approval

OCT-461201 is under clinical development by Oxford Cannabinoid Technologies and currently in Phase I for Visceral Pain.

Jun 18, 2024 - 04:00
OCT-461201 is under clinical development by Oxford Cannabinoid Technologies and currently in Phase I for Visceral Pain.
Read the original article

Tags:

Previous Article

MAS-825 by Novartis for Coronary Artery Disease (CAD) (Ischemic Heart Disease): ...

Next Article

OCT-461201 by Oxford Cannabinoid Technologies for Neuropathic Pain (Neuralgia): ...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AGEPHA Pharma’s LODOCO gets US FDA approval for cardiovascular disease

AGEPHA Pharma’s LODOCO gets US FDA approval for cardiov...

Jun 21, 2023

Market cap upturn for top 20 biopharma companies with obesity drug successes in 2023

Market cap upturn for top 20 biopharma companies with o...

Mar 1, 2024

Here’s why obesity grew so quickly worldwide, and where that’s starting to change

Here’s why obesity grew so quickly worldwide, and where...

Jun 8, 2023